RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature

Cancer Genetics and Cytogenetics

Volumn 185, Issue 1, 2008, Pages 47-50

  De Braekeleer, Étienne ^a,b   Douet Guilbert, Nathalie ^a,b,c   Le Bris, Marie Josée ^c   Morel, Frédéric ^a,b,c   Férec, Claude ^b,c   De Braekeleer, Marc ^a,b,c  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b INSERM   (France)

^c CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; HEMOGLOBIN; HLA DQ2 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; BLAST CELL; BONE MARROW CELL; CASE REPORT; CHROMOSOME 16Q; CHROMOSOME 21Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DYSPNEA; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FUSION; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN GENOME; IMMUNOPHENOTYPING; KARYOTYPE; LYMPHOCYTE COUNT; MONOCYTE; MTG16 GENE; NEUTROPHIL COUNT; PANCYTOPENIA; PRIORITY JOURNAL; RUNT RELATED TRANSCRIPTION FACTOR GENE; THROMBOCYTE COUNT;

AGED; CHROMOSOME DELETION; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; ONCOGENE PROTEINS, FUSION; PHOSPHOPROTEINS; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

ALIAS;

EID: 47549088627     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.04.011     Document Type: Article

References (22)

1. De Braekeleer M. Three steps mutation model of carcinogenesis. Med Hypotheses 14 (1984) 363-371
2. Douet-Guilbert N., Morel F., Le Bris M.J., Herry A., Morice P., Bourquard P., Banzakour S., Le Calvez G., Marion V., Berthou C., and De Braekeleer M. Rearrangement of the MLL gene in acute myeloblastic leukemia: report of two rare translocations. Cancer Genet Cytogenet 157 (2005) 169-174
3. Shaffer L. Tommerup. ISCN (2005): an international system for human cytogenetic nomenclature (2005), S. Karger, Basel
4. Douet-Guilbert N., Morel F., Le Bris M.J., Herry A., Le Calvez G., Marion V., Abgrall J.F., Berthou C., and De Braekeleer M. Fluorescence in situ hybridization study of TEL/AML1 fusion in B-cell acute lymphoblastic leukemia (1984-2002). Cancer Genet Cytogenet 114 (2003) 143-147
5. Erickson P., Gao J., Chang K.S., Look T., Whisenant E., Raimondi S., Lasher R., Trujillo J., Rowley J., and Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80 (1992) 1825-1831
6. Raimondi S.C., Kalwinsky D.K., Hayashi Y., Behm F.G., Mirro J., and Williams D.L. Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet 40 (1989) 13-27
7. Gamou T., Kitamura E., Hosoda F., Shimizu K., Shinohara K., Hayashi Y., Nagase T., Yokoyama Y., and Ohki M. The partner gene of RUNX1 in t(16;21) myeloid malignancies is a novel member of the MTG8 (ETO) family. Blood 91 (1998) 4028-4037
8. Pedersen-Bjergaard J., and Andersen M.K. Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality. Haematologica 83 (1998) 481-482
9. Pedersen-Bjergaard J., Andersen M.K., and Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 16 (1998) 1897-1898
10. Liu Y.C., Ito Y., Hsiao H.H., Sashida G., Kodama A., Ohyashiki J.H., and Ohyashiki K. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 171 (2006) 9-16
11. Kondoh K., Nakata Y., Furuta T., Hosoda F., Gamou T., Kurosawa Y., Kinoshita A., Ohki M., Tomita Y., and Mori T. A pediatric case of secondary leukemia associated with t(16;21)(q24;q22)exhibiting the chimeric AML1-MTG16 gene. Leuk Lymphoma 43 (2002) 415-420
12. Salomon-Nguyen F., Busson-Le Coniat M., Lafage-Pochitaloff M., Mozziconacci J., Berger R., and Bernard O.A. AML1-MTG16 fusion gene in therapy-related acute leukemia with t(16;21)(q24;q22): two new cases. Leukemia 14 (2000) 1704-1705
13. La Starza R., Sambani C., Crescenzi B., Matteucci C., Martelli M.F., and Mecucci C. AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after breast cancer. Haematologica 86 (2001) 212-213
14. Kitabayashi I., Ida K., Morohoshi F., Yokoyama A., Mitsuhashi N., Shimizu K., Nomura N., Hayashi Y., and Ohki M. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG(ETO/CDR) family, MTGR1. Mol Cell Biol 18 (1998) 846
15. Hoogeveen A.T., Rossetti S., Stoyanova V., Schonkeren J., Fenaroli A., Schiaffonati L., et al. The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t(16;21)-positive myeloid malignancies. Oncogene 21 (2002) 6703-6712
16. Rossetti S., Van Unen L., Touw I.P., Hoogeveen A.T., and Sacchi N. Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation. Oncogene 24 (2005) 5325-5332
17. Traweek S.T., Slovak M.L., Nademanee A.P., Brynes R.K., Niland J.C., and Forman S.J. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 84 (1994) 957-963
18. Nylund S.J., Ruutu T., Saarinen U., and Knuutila S. Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haematopoietic malignancies. Br J Haematol 88 (1994) 778-783
19. Berger R., Le Coniat M., Romana S.P., and Jonveaux P. Secondary acute myeloblastic leukemia with t(16;21)(q24;q22) involving the RUNX1 gene. Hematol Cell Ther 38 (1996) 183-186
20. Shimada M., Ohtsuka E., Shimizu T., Matsumoto T., Matsushita K., Tanimoto F., and Kajii T. A recurrent translocation, t(16;21)(q24;q22), associated with acute myelogenous leukemia: identification by fluorescence in situ hybridization. Cancer Genet Cytogenet 96 (1997) 102-105
21. Takeda K., Shinohara K., Kameda N., and Ariyoshi K. A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide. Int J Hematol 67 (1998) 179-186
22. Jeandidier E., Dastugue N., Mugneret F., Lafage-Pochitaloff M., Mozziconacci M.J., Herens C., Michaux L., Verellen-Dumoulin C., Talmant P., Cornillet-Lelebvre P., Luquet I., Charrin C., Barin C., Collonge-Rame M.A., Perot C., Van den Akker J., Gregoire M.J., Jonveaux P., Baranger L., Eclache-Saudreau V., Pages M.P., Cabrol C., Terre C., Berger R., and on behalf of the Groupe Francais de Cytogenetique Hematologique (GFCH). Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoietic disorders: a collaborative retrospective study of the Groupe Français de Cytogénétique Hématologique. Cancer Genet Cytogenet 166 (2006) 1-11